Nörodejenerasyon ve Yaşlılık: Hücresel Yaklaşımlar
Özet
Bu derleme çalışması, yaşlanma süreci ile nörodejeneratif hastalıklar arasındaki hücresel ve moleküler mekanizmaları kapsamlı bir şekilde incelemektedir. Yaşlanma; genomik istikrarsızlık, telomer kısalması, proteostaz kaybı, hücresel iletişim değişiklikleri ve mitokondriyal disfonksiyon gibi temel biyolojik ayırt edici özelliklerle karakterize edilmekte olup, Alzheimer, Parkinson ve Amyotrofik Lateral Skleroz gibi kronik nörodejeneratif rahatsızlıkların gelişimi için en önemli risk faktörüdür. Hücresel yaşlanma (senesens) sürecinde, DNA hasar yanıtı (DDR) mekanizmalarının p53 ve p21 siklin-bağlı kinaz inhibitörleri üzerinden sürekli aktivasyonu ile geri dönüşsüz büyüme durması gerçekleşmekte ve SASP bileşenlerinin salınımı nöroenflamasyon ile doku hasarını tetiklemektedir. Terminal olarak farklılaşmış olgun nöronlar normal şartlarda G0 fazında sessiz kalırken, patolojik durumlarda siklinler ve CDK'ların hatalı indüksiyonuyla hücre döngüsüne kontrolsüz bir şekilde yeniden girmekte, ancak tamamlayamadıkları bu abortif döngü sonucunda apoptotik hücre ölümüyle karşılaşmaktadır. Hücresel redoks dengesinin bozulması ve reaktif oksijen türlerinin (ROS) aşırı birikimi; şiddetli oksidatif strese, mitokondriyal DNA mutasyonlarına, ATP üretiminin azalmasına ve özellikle sinaptik mitokondri hasarına yol açarak sinaptik kayba ve bilişsel gerilemeye zemin hazırlamaktadır. Son olarak, bir post-translasyonel modifikasyon mekanizması olan SUMOylasyon; nükleer DNA tek iplik onarımı (TDP1) ve mitokondriyal fizyon-füzyon dinamiklerinin (DRP1) düzenlenmesinde kritik roller üstlenmekte olup, değişken oksidatif stres koşullarındaki yanıtları ve patojenik proteinlerin toksisitesini doğrudan modüle etmektedir.
Referanslar
Kritsilis M, V Rizou S, Koutsoudaki PN, et al. Ageing, Cellular Senescence and Neurodegenerative Disease. Int J Mol Sci. 2018;19(10):2937.
Kovacs GG, Lee VM, Trojanowski JQ. Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathol. 2017;27(5):675-690.
Pratt WB, Gestwicki JE, Osawa Y, et al. Targeting Hsp90/Hsp70-
based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol. 2015;55:353-371.
Prince M, Ali GC, Guerchet M, et al. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23.
Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217-231.
Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017;19(1):1-10.
Kirkwood TB, Melov S. On the programmed/non-programmed nature of ageing within the life history. Curr Biol. 2011 Sep 27;21(18):701-707.
Kirkwood TB, Feder M, Finch CE, et al. What accounts for the wide variation in life span of genetically identical organisms reared in a constant environment? Mech Ageing Dev. 2005;126(3):439-443.
Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15(7):482-496.
Howcroft TK, Campisi J, Louis GB, et al. The role of inflammation in age-related disease. Aging (Albany NY). 2013;5(1):84-93.
Salama R, Sadaie M, Hoare M, et al. Cellular senescence and its effector programs. Genes Dev. 2014;28(2):99-114.
Nardella C, Clohessy JG, Alimonti A, et al. Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 2011;11(7):503-511.
Sedelnikova OA, Horikawa I, Zimonjic DB, et al. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol. 2004;6(2):168-170.
Rodier F, Coppe JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973-979.
Fumagalli M, Rossiello F, Clerici M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol. 2012;14(4):355-365.
Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr Gerontol Geriatr Res. 2012;2012:170276.
Boccardi V, Pelini L, Ercolani S, et al. From cellular senescence to Alzheimer's disease: The role of telomere shortening. Ageing Res Rev. 2015;22:1-8.
Barnum KJ, O'Connell MJ. Cell cycle regulation by checkpoints. Methods Mol Biol. 2014;1170:29-40.
Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 2009;28(33):2925-2939.
Frade JM, Ovejero-Benito MC. Neuronal cell cycle: the neuron itself and its circumstances. Cell Cycle. 2015;14(5):712-720.
Kristiansen M, Ham J. Programmed cell death during neuronal development: the sympathetic neuron model. Cell Death Differ. 2014 Jul;21(7):1025-1035.
Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer’s disease? J Cell Biol. 1996;132:413-425.
Bonda DJ, Evans TA, Santocanale C, et al. Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging (Milano). 2009;1:382-388.
Harman D. Aging: a theory based on free radical and radiation
chemistry. J Gerontol. 1956;11:298-300.
Kishida KT, Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. Antioxid Redox Signal. 2007;9:233-244.
Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest. 2013;123:951-957.
Massaad CA, Klann E. Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal. 2011;14(10):2013-2054.
Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18(3):283-293.
Reddy PH. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal. 2007;9(10):1647-1658.
Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008;14(2):45-53.
Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease. CNS Spectr. 2009;14(8):8-18.
Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA. 2004;101(29):10726-10731.
Swerdlow RH, Parks JK, Cassarino DS, et al. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 1997;49(4):918-925.
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787-795.
Mungarro-Menchaca X, Ferrera P, Moran J, et al. beta-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res. 2002;68(1):89-96.
Menzies RA, Gold PH. The turnover of mitochondria in a variety of tissues of young adult and aged rats. J Biol Chem. 1971;246(8):2425-2429.
Sen P, Shah PP, Nativio R, et al. Epigenetic Mechanisms of Longevity and Aging Cell. 2016;166(4):822-839.
Kovacs GG, Lee VM, Trojanowski JQ. Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathol. 2017;27(5):675-690.
Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 2013;82:357-385.
Princz A, Tavernarakis N. SUMOylation in Neurodegenerative Diseases. Gerontology. 2020;66(2):122-130.
Wilkinson KA, Nakamura Y, Henley JM. Targets and consequences of protein SUMOylation in neurons. Brain Res Rev. 2010;64(1):195-212.
Matunis MJ, Rodriguez MS. Concepts and Methodologies to Study Protein SUMOylation: An Overview. Methods Mol Biol. 2016;1475:3-22.
Hudson JJ, Chiang SC, Wells OS, et al. SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Nat Commun. 2012;3:733.
Zunino R, Schauss A, Rippstein P, et al. The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci. 2007;120(7):1178-1188.
Bossis G, Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol Cell. 2006;21(3):349-357.
